AstraZeneca PLC - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AZN New York 2830 www.astrazeneca.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AstraZeneca PLC

From Padcev to PF-08634404: Pfizer's Oncology Growth Push - Aug 31st, 2026 9:37 am
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger - Aug 30th, 2026 8:29 pm
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors - Aug 29th, 2026 8:35 am
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY - Aug 28th, 2026 3:18 pm
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell? - Aug 28th, 2026 9:45 am
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease - Aug 28th, 2026 4:58 am
Cytotoxic Drugs Market Report Now Available — Forecasts Market Growth from $16.21B (2026) to $21.06B by 2031, Profiling Pfizer, Roche, Novartis, AstraZeneca, Sanofi, and 15 Other Key Players - Aug 28th, 2026 2:18 am
AstraZeneca (LSE:AZN) Reports Positive TEZSPIRE Phase 3 Results, Is The Discount Too Wide? - Aug 27th, 2026 11:08 pm
What Is AstraZeneca (LSE:AZN) Signaling With Its Latest Late Stage Trial Results? - Aug 27th, 2026 8:17 pm
Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent? - Aug 27th, 2026 2:29 pm
AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Success - Aug 27th, 2026 1:10 pm
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study - Aug 27th, 2026 10:11 am
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study - Aug 27th, 2026 8:57 am
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves - Aug 27th, 2026 8:48 am
Can Eli Lilly's Oncology Portfolio Drive Growth Beyond GLP-1 Drugs? - Aug 27th, 2026 7:38 am
New data could widen use of AstraZeneca, Amgen immune disease drug - Aug 27th, 2026 5:58 am
Amgen-AstraZeneca’s Tezspire nets another Phase III inflammatory disease win - Aug 27th, 2026 5:30 am
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints - Aug 27th, 2026 5:00 am
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS - Aug 27th, 2026 12:00 am